Skip to content

The effect of nalbuphine combined with sufentanil on postoperative recovery quality of spinal surgery patients

The effect of nalbuphine combined with sufentanil on postoperative recovery quality of spinal surgery patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400094717
Enrollment
Unknown
Registered
2024-12-26
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative rehabilitation

Interventions

Experimental group:Dilute 2mg/kg of nalbuphine and 1 µ g/kg of sufentanil citrate with physiological saline to 100ml for postoperative analgesia. Parameter settings: background dose 2ml/h, bolus 0.5ml
control group:Dilute 2 µ g/kg of sufentanil citrate with physiological saline to 100ml for postoperative analgesia. Parameter settings: background dose 2ml/h, bolus 0.5ml/time, locking time 15min. Mai

Sponsors

Qingdao Municipal Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: ASA I-III grade patients aged = 18 years, undergoing elective spinal surgery OLIF under general anesthesia, with a BMI = 18.5 kg/m and a weight of 29 kg/m2

Exclusion criteria

Exclusion criteria: 1) Poor compliance and inability to cooperate with surgery; (2) Patients with severe organic lesions (coronary heart disease, bronchial asthma, severe hypertension, severe hematological dysfunction, liver and kidney function, and significant electrolyte abnormalities); (3) Grade II and above atrioventricular block, bradycardia (HR<50 beats/minute), hypotension (SBP<90mmHg); (4) History of neurological disorders; History of chronic pain; Drug addiction and alcoholism; Long term history of opioid use; (5) Individuals allergic to components of nalbuphine hydrochloride or sufentanil, and patients with a history of opioid allergy; (6) Patients with limited gastric emptying and gastroparesis; (7) Patients with weakened intestinal peristalsis and intestinal obstruction; (8) Individuals who have participated in clinical trials of other drugs within the past 4 weeks; (9) Accompanied by other circumstances, the researchers believe that patients who are not suitable for inclusion

Design outcomes

Primary

MeasureTime frame
Postoperative QoR-15 scores on day 1, 3, and 5;Postoperative patient satisfaction related indicators;

Secondary

MeasureTime frame
Pain related indicators;Postoperative recovery indicators;

Countries

China

Contacts

Public ContactXu Lin

Qingdao Municipal Hospital

pndable2021@sina.com+86 186 7895 1375

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026